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UCL Institute of Liver and Digestive Health, UCL Medical School, London, United KingdomA story of talent, passion and honesty
Scott L. Friedman, Fishberg Professor of Medicine, and Chief of the
Division of Liver Diseases, Mount Sinai School of Medicine in New
York, USA, received the EASL International Recognition Award
during the 2012 International Liver Congress in Barcelona and I
was honored to introduce the Award in front of the massive audi-
ence of the plenary session. The preparation of the presentation
for the Award to Scott Friedman gave me the opportunity to elab-
orate on the meaning of the word ‘‘recognition’’, i.e. credit,
acknowledgement, appreciation, respect. Indeed, any of these
words reﬂects the gratitude of the Hepatology community for
the contribution of Scott Friedman to the great progress of the
scientiﬁc knowledge in this area of medicine and the advance-
ments in clinical practice.
Scott L. Friedman is a 1979 graduate of Mount Sinai School of
Medicine. After graduation, he became a Medical Resident at the
Beth Israel Hospital, Harvard Medical School, Boston, then a
Gastroenterology Fellow at UCSF before taking a faculty position
there, which he held for 10 years. During a 1995–96 sabbatical
from UCSF, he was a Fulbright Scholar and Visiting Professor at
the Weizmann Institute of Science in Israel, in the laboratory of
Dr. Moshe Oren. In 1997, Scott returned to the Mount Sinai
School of Medicine where he held the position of Fishberg Profes-
sor of Medicine. Since 2001, he is Chief of the Division of Liver
Diseases. In 2003, Scott was awarded the Hans Popper Interna-
tional Liver Research Prize, recognizing his pioneering work into
mechanisms and treatments of hepatic ﬁbrosis. He has authored
over 300 scientiﬁc articles, and he has served as mentor to over
50 students, physicians, and postdoctoral trainees. As President
of the American Association for the Study of Liver Diseases in
2009, Scott oversaw several major new initiatives that acceler-
ated the growth of this organization.
Liver ﬁbrosis is the area where Scott has provided a funda-
mental contribute with his pioneering research in the 1980s
and with the following almost 30 years of research activity
always at the top level. His work has spawned an entire ﬁeld that
is now realizing its translational and therapeutic potential, withJournal of Hepatology 20
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als, and has been continuously funded by the NIH since 1985.
The biology of hepatic stellate cells (HSC, once called fat-storing
cells or lipocytes) and their role in hepatic ﬁbrogenesis has been
the leitmotiv of Scott’s work representing the ideal continuation
of the discoveries and intuitions of earlier studies by Drs. Hans
Popper and Fenton Schaffner at Mount Sinai emphasizing HSC’s
potential importance in liver disease [1].
While it is not correct to state that Scott Friedman was the
ﬁrst to isolate and characterize the hepatic stellate cell, it is true
that Scott discovered the Formula 1 engine hidden behind this,
once overlooked, liver cell type. Following the early studies of
Popper and Shaffner [1], the role of HSCs in liver physiology
and their implication in ﬁbrogenesis had been speculated mainly
on morphological/biochemical basis [2,3]. The ﬁrst isolation and
in vitro culture of rat HSC was described by Knook and co-work-
ers in 1982 [4], followed by the in vitro demonstration of their
collagen synthetic activity obtained by the same group [5]. Scott’s
ﬁrst appearance on the HSC stage with two of the most quoted
papers in the history of Hepatology is in the mid 1980’s and
includes Scott’s famous recipe for the isolation of HSC employing
gradients of Stractan [6,7]. Regardless, in those years, the efforts
of Scott, of his pioneer mentor in San Francisco, Monty Bissell,
and of others were not fully appreciated. Indeed, until 1988/89,
when two ‘‘revolutionary’’ studies were ﬁnally published [8,9],12 vol. 57 j 244–245
JOURNAL OF HEPATOLOGY
it was believed that hepatocytes were the main source of ﬁbrotic
extracellular matrix following chronic liver tissue injury. A prove
of this is represented by the negative reviewer’s comments to the
ﬁrst NIH grant submission ‘‘The role of lipocytes in hepatic ﬁbro-
sis’’ that Scott submitted in 1985: ‘‘The major weaknesses of this
application include a number of substantive methodological prob-
lems which have not been adequately considered. These problems
will cast doubt on the validity of any data obtained and may impair
Dr. Friedman’s ability to compete for research funding as an indepen-
dent investigator.’’ This part of Scott Friedman’s story, framed in
the enormous success that his ideas have received in the follow-
ing 20 years, represents a major teaching point for any young
investigator approaching a new frontier in scientiﬁc develop-
ment, i.e. never give up!
By the end of the 1980’s, the ﬁeld of liver ﬁbrosis and HSC
biology was mature for take-off. Besides its contribution to the
ﬁnal elucidation of the key pro-ﬁbrogenic role of HSC, the major
input of Scott Friedman was to launch this area into its cellular
and molecular complexity with the consequent discovery of the
relative mechanisms as witnessed by the ﬁrst two studies
approaching the intricacy of the relationship between activated
HSC and the surrounding extracellular matrix [10,11]. In 1989,
Scott contributed an additional key step, i.e. the initial elucida-
tion of the role of polypeptide growth factor and their receptors
in the biology of HSC and, in general, in the hepatic ﬁbrogenic
process [12]. In that occasion, I had the honor to publish my ﬁrst
paper on HSC dealing with the same topic back to back with
Scott’s paper on the same issue of Journal of Clinical Investigation
[13]. It is very worth mentioning that Scott had helped me in
establishing my ﬁrst HSC culture by revealing key methodologi-
cal tricks. Although this area was becoming extremely competi-
tive, I am aware that Scott assisted anybody who requested his
help with the same spirit and the same honesty and became
the leader of the ‘‘ﬁbrosis boys (and girls)’’, as the Mother of
Hepatology, Dame Sheila Sherlock, used to call us.
The transition of liver ﬁbrosis research from its middle age to
a ﬂourishing renaissance coincided with the discovery of the hep-
atitis C virus and the introduction of anti-viral therapies. In the
early 1990’s, two/third of the abstracts presented at international
liver meetings were focused on viral hepatitis and relative treat-
ments with a marginal space for any other area of Hepatology
research. Regardless, the ﬁbrosis boys worked with passion and
continuity unfolding day after day the intricate pathways of liver
ﬁbrogenesis. HSC slowly became the stars of liver cell biology and
this relatively small community of young physicians and scien-
tists became increasingly recognized and established. Without
any doubt, Scott Friedman was the catalyst of this success. In
addition, he had a key role in making this community a really
friendly one. There was indeed competition but also great respect
for each other and a great deal of collaboration. Meeting at the
ﬁbrosis oral and poster sessions at the AASLD and EASL annual
meetings became a classic and joyful gathering of friends.
Slowly but steadily the concepts derived from the studies on
liver ﬁbrogenesis conquered the attention of clinical hepatolo-
gists with an increasing awareness that any successful treatment
of chronic liver disease must be monitored in terms of ﬁbrosis
progression and regression. This led to a re-evaluation of liver
biopsy as a ‘‘gold-standard’’ for the assessment of liver ﬁbrosis,
the development of non-invasive methods for staging and prog-Journal of Hepatology 201nosis and a the logical introduction of regression of ﬁbrosis as a
main end point in clinical trials, as conﬁrmed by more than 90
ongoing clinical trials testing anti-viral drugs (www.clinicaltri-
als.gov). Undoubtedly, the roots of this expanding tree are in
the UCSF laboratory where Scott Friedman moved his ﬁrst steps
in ﬁbrosis research.
The ultimate dream of the liver ﬁbrosis community was and
still is the development of effective anti-ﬁbrotic drugs to be asso-
ciated with the causative therapies of ﬁbrogenic chronic liver dis-
eases and in some instances as a single treatment. After 25 years
of intensive research, there is not yet an antiﬁbrotic agent that
could be introduced in clinical practice and all these efforts seem
to be ‘‘lost in translation’’ [14]. However, the maturity reached in
this area of investigation and the joint efforts of academia and
industry in this direction are encouraging. In this context, it is
even more heartening that Scott Friedman has recently been
appointed Dean for Therapeutic Discovery at Mount Sinai. There-
fore, the EASL International Recognition Award to Scott Friedman
is not just an acknowledgment to a brilliant scientiﬁc career but a
wish for further success and advancement.References
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